Literature DB >> 32934739

Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer.

Ning Yang1, Chuanming Li2, Xiao Han3, Zhihua Feng4, Feng Qiu5, Junqing Han1.   

Abstract

Associations of metastasis-associated protein 1 (MTA1) expression with computed tomography (CT) features, pathology and prognosis of elderly patients with non-small cell lung cancer (NSCLC), and its clinical significance were explored. A total of 98 elderly patients with NSCLC were selected and underwent CT examination. The expression of MTA1 in carcinoma tissues and para-carcinoma normal tissues was detected via immunohistochemistry, and its associations with CT features, pathology and prognosis were analyzed. The results manifested that the expression of MTA1 in carcinoma tissues was significantly higher than that in para-carcinoma normal tissues, and it was associated with the degree of differentiation, stage and lymph node metastasis (P<0.05). Besides, the high expression of MTA1 was also related to the spicule sign, pleural indentation and lymph node metastasis (P<0.05) as well as the CT perfusion parameter capillary permeability (PMB) (P<0.05), but not to blood volume (BV), blood flow (BF) or time to peak (TTP). Moreover, the patients with high expression of MTA1 had significantly shorter survival time and a remarkably lower 5-year survival rate than those with low expression of MTA1 (P<0.05). In conclusion, MTA1 plays a certain role in the occurrence and development of NSCLC in elderly patients and has an association with their prognosis, which can provide references for the treatment and prognosis of NSCLC, with important clinical significance.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  computed tomography; metastasis-associated protein 1; non-small cell lung cancer in the elderly; prognosis

Year:  2020        PMID: 32934739      PMCID: PMC7471726          DOI: 10.3892/ol.2020.12034

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  CT screening for lung cancer.

Authors:  Stephen J Swensen
Journal:  AJR Am J Roentgenol       Date:  2002-10       Impact factor: 3.959

2.  Expression of the MTA1 mRNA in advanced lung cancer.

Authors:  Hidefumi Sasaki; Satoru Moriyama; Yoshiaki Nakashima; Yoshihiro Kobayashi; Haruhiro Yukiue; Masahiro Kaji; Ichiro Fukai; Masanobu Kiriyama; Yosuke Yamakawa; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2002-02       Impact factor: 5.705

3.  LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.

Authors:  L Liu; X-Y Zhou; J-Q Zhang; G-G Wang; J He; Y-Y Chen; C Huang; L Li; S-Q Li
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-12       Impact factor: 3.507

4.  A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer.

Authors:  Nirmala Jagadish; Deepak Parashar; Namita Gupta; Sumit Agarwal; Aditi Sharma; Rukhsar Fatima; Vaishali Suri; Rajive Kumar; Anju Gupta; Nirmal Kumar Lohiya; Anil Suri
Journal:  Oncoimmunology       Date:  2016-02-09       Impact factor: 8.110

Review 5.  Myocardial CT perfusion imaging for ischemia detection.

Authors:  Patricia Carrascosa; Carlos Capunay
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

6.  Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.

Authors:  Juheon Lee; Yi Cui; Xiaoli Sun; Bailiang Li; Jia Wu; Dengwang Li; Michael F Gensheimer; Billy W Loo; Maximilian Diehn; Ruijiang Li
Journal:  Eur Radiol       Date:  2017-08-07       Impact factor: 5.315

7.  Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Q Wang; Q Wang; S F Wang; L J Jiao; R X Zhang; Y Zhong; J Zhang; L Xu
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

8.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

9.  Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer.

Authors:  Xiaoxia Zhu; Yu Guo; Xiangzhao Li; Yanqing Ding; Longhua Chen
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

10.  Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.

Authors:  Yun Cui; Fuming Zhang; Chunkai Zhu; Liang Geng; Tongde Tian; Huaimin Liu
Journal:  Oncotarget       Date:  2017-03-14
View more
  1 in total

1.  MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm.

Authors:  Wei Wang; Zaoxiu Hu; Mingsheng Ma; Haoyuan Yin; Yunchao Huang; Guangqiang Zhao; Xin Cui; Qinling Sun; Yantao Yang; Yichen Yang; Biying Wang; Lianhua Ye
Journal:  Ther Clin Risk Manag       Date:  2021-12-03       Impact factor: 2.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.